Browse > Article

Pharmacokinetic Interaction Between Atorvastatin and Nifedipine  

Moon, Hong-Seop (Department of pharmacy, Chosun University Hospital, College of Pharmacy, Chosun University)
Choi, Jun-Shik (Department of pharmacy, Chosun University Hospital, College of Pharmacy, Chosun University)
Publication Information
Korean Journal of Clinical Pharmacy / v.20, no.1, 2010 , pp. 25-29 More about this Journal
Abstract
The purpose of this study was to investigate the effect of atorvastatin on the pharmacokinetics of nifedipine (6 mg/kg) after oral administration of nifedipine with or without atorvastatin (0.5 and 2.0 mg/kg) in rats, and also was to evaluate to the effect of atorvastatin on the CYP3A4 activity. The 50% inhibiting concentration ($IC_{50}$) values of atorvastatin on CYP3A4 activity is 46.1 ${\mu}M$. Atorvastatin inhibited CYP3A4 enzyme activity in a concentration-dependent manner. Coadministration of atorvastatin increased significantly (p<0.05, 2.0 mg/kg) the plasma concentration-time curve (AUC) and the peak concentration ($C_{max}$) of nifedipine compared to the control group. The relative bioavailability (RB%) of nifedipine was increased from 1.15- to 1.37-fold. Coadministration of atorvastatin did not significantly change the terminal half-life ($T_{1/2}$) and the time to reach the peak concentration ($T_{max}$) of nifedipine. Based on these results, we can make a conclusion that the significant changes of these pharmacokinetic parameters might be due to atorvastatin, which possesses the potency to inhibit the metabolizing enzyme (CYP3A4) in the liver and intestinal mucosa, and also inhibit the P-glycoprotein (P-gp) efflux pump in the intestinal mucosa. It might be suggested that atorvastatin altered disposition of nifedipine by inhibition of both the first-pass metabolism and P-glycoprotein efflux pump in the small intestine of rats. In conclusion, the presence of atorvastatin significantly enhanced the oral bioavailability of nifedipine, suggesting that concurrent use of atorvastatin with nifedipine should require close monitoring for potential drug interation.
Keywords
Nifedipine; Atorvastatin; Pharmacokinetics; Bioavailability; CYP3A4; P-gp;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Boyd RA, Stern RH, Stewart BH, et al., Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 2000; 40: 91-8.   DOI   ScienceOn
2 Hong SP, Chang KS, Choi DH, et al., Effect od Atorvastatin on the Pharmacokinetics of Diltiazem and Its main metabolite, Desacetyldiltiazem, in rats. Arch Pharm Res 2007; 30; 90-95.   과학기술학회마을   DOI
3 Rocci ML, Jusko WJ. LAGRAN program for area and moments in pharmacokinetic analysis. Computer Programs in Biomedicine 1983; 16: 203-9.   DOI   ScienceOn
4 Sorkin E M, Clissold SP, Brogden RN. Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders. Drugs 1985; 30: 182-7.   DOI   ScienceOn
5 Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-90.   DOI   ScienceOn
6 Ito K, Kusuhara H, Sugiyama Y. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption - theoretical approach. Pharm Res 1999; 16: 225-31.   DOI   ScienceOn
7 Choi BC, Choi JS. Pharmacokinetic interaction between simvastatin and nicardipine. Kor J Clin Pharm 2009; 19: 32-36.   과학기술학회마을
8 Choi DH, Li C, Choi JS. Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. Eur J Durg Metabol 2009; 34: 163- 168.   DOI   ScienceOn
9 Grundy JS, Kherani R, Foster RT. Sensitive highperformance liquid chromatographic assay for nifedipine in human plasma utilizing ultraviolet detection. J Chromatogr B Biomed Appl 1994; 654: 146-52.   DOI   ScienceOn
10 Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-90.   DOI   ScienceOn
11 Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 1970; 30: 1174-80.
12 Hokama N, Hobara N, Sakai M, et al., Influence of nicardipine and nifedipine on plasma carvedilol disposition after oral administration in rats. J Pharm Pharmacol 2002; 54: 821-26.   DOI   ScienceOn
13 Ford JM. Modulators of multidrug resistance preclinical studies. Hematol Oncol Clin N Am 1995; 9: 337-42.
14 Fruehauf JP, Manetta A. Use of extreme drug resistance assay to evaluate mechanisms of resistance in ovarian cancer: Taxol resistance and MDR1 expression. Contrib Gynecol Obstet 1994; 19: 39-45.
15 Endo T, Kimura O, Sakata M. Effects of P-glycoprotein inhibitors on cadmium accumulation in cultured renal epithelial cells, LLC-PK1, and OK. Toxicol Appl Pharmacol 2002; 185: 166-72.   DOI   ScienceOn
16 Lea AP, McTavish D. Atorvastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs 1997; 53: 828-47.   DOI   ScienceOn
17 Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet 2003; 42: 1141-60.   DOI   ScienceOn
18 Wu X, Whitheld LR, Stewart, BH. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and proton-monocarboxylic acid co-transporter. Pharm Res 2000; 17: 209-15.   DOI   ScienceOn
19 Holtzman CW, Wiggins BS, Spinler SA. Role of Pglycoprotein in Statin Drug Interactions. Pharmacotherapy 2006; 26: 1601-07.   DOI   ScienceOn
20 Mousa O, Brater DC, Sunblad KJ, Hall SD. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther 2000; 67: 267-74.   DOI   ScienceOn
21 Choi DH, Chang KS, Hong SP, et al., Effect of Atorvastatin on the Intravenous and Oral Pharmacokinetics of Verapamil in Rat. Biopharm Drug Dispos 2008; 29: 45- 50.   DOI   ScienceOn
22 Watkins PB, Wrighton SA, Schuetz EG, et al., Identification of glucocorticoid-inducible cytochromes P- 450 in the intestinal mucosa of rats and man. J Clin Invest 1987; 80: 1029-35.   DOI
23 Henry PD. Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. Am J Cardiol 1980; 46: 1047-53.   DOI   ScienceOn
24 Guengerich FP, Brian WR, Iwasaki M. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4, J Med Chem 1991; 4: 1838-44.
25 Iribarne C, Dréano LG, Bardou JF, Ménez G, et al., Interaction of methadone with substrates of human hepatic cytochrome P450 3A4. Toxicology 1997; 117: 13-9.   DOI   ScienceOn
26 Kolars JC, Schmiedlin-Ren P, Dobbins 3rd WO, et al., Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia. Gastroenterology 1992; 102: 1186-92.
27 Gan SL, Moseley MA, Khosla B, et al., CYP3A-Like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: interaction between the two biochemical barriers to intestinal transport. Drug Metab Dispos 1996; 24: 344-50.
28 Watkins PB. The barrier function of CYP3A4 and Pglycoprotein in the small bowel. Adv Drug Deliv Rev 1996; 27: 161-7.
29 Wacher VH, Silverman JA, Zhang Y, et al., Role of Pglycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 1998; 87: 1322-8.   DOI
30 Ito K, Kusuhara H, Sugiyama Y. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption theoretical approach. Pharm Res 1999; 16: 225-31.   DOI   ScienceOn
31 Chaudhary PM, Robinson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991; 66: 85-90.   DOI   ScienceOn
32 Raemsch KD, Sommer JC. Pharmacokinetics and metabolism of nifedipine. Hypertension 1983; 5: 18-24.
33 Van Asperen J, Van Tellingen O, Sparreboom A, et al., Enhanced oral bilavailability of diltiazem in mice treated with the p-glycoprotein blocker. Br J Cancer 1997; 76: 1181-87.   DOI   ScienceOn
34 Walter DG, Gruchy BS, Renwick AG, et al., The first pass metabolism of nifedipine in man. Br J Clin Pharmacol 1984; 18: 951-6.   DOI   ScienceOn